Emrullah Yilmaz
Experienced in Angiosarcoma of the Scalp

Dr. Emrullah Yilmaz

Otolaryngology
9500 Euclid Avenue, 
Cleveland, OH 
On Staff At
Clinical Trials:Currently Recruiting for 2 Trials
Experienced in Angiosarcoma of the Scalp
9500 Euclid Avenue, 
Cleveland, OH 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Emrullah Yilmaz is an Otolaryngologist in Cleveland, Ohio. Dr. Yilmaz is rated as an Experienced provider by MediFind in the treatment of Angiosarcoma of the Scalp. His top areas of expertise are Anaplastic Thyroid Cancer, Thyroid Cancer, Head and Neck Squamous Cell Carcinoma (HNSCC), Tissue Biopsy, and Thyroidectomy.

His clinical research consists of co-authoring 29 peer reviewed articles and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Otolaryngology
Licenses
Internal Medicine in NM
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medical Mutual
  • HMO
  • PPO
Oscar
  • EPO
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 5 Less Insurance Carriers -

Locations

Cleveland Clinic Main Campus
9500 Euclid Avenue, Cleveland, OH 44195

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients With Unresectable Stage III or Stage IV Melanoma
Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients With Unresectable Stage III or Stage IV Melanoma
Enrollment Status: Recruiting
Publish Date: October 15, 2025
Intervention Type: Procedure, Biological
Study Drugs: Ipilimumab, Nivolumab, Sargramostim
Study Phase: Phase 2/Phase 3
Establishment of a National Biorepository to Advance Studies of Immune-Related Adverse Events
Establishment of a National Biorepository to Advance Studies of Immune-Related Adverse Events
Enrollment Status: Recruiting
Publish Date: October 08, 2025
Intervention Type: Procedure, Other
A Phase II Randomized Study of Adjuvant Versus NeoAdjuvant Pembrolizumab (MK-3475) for Clinically Detectable Stage III-IV High-Risk Melanoma
A Phase II Randomized Study of Adjuvant Versus NeoAdjuvant Pembrolizumab (MK-3475) for Clinically Detectable Stage III-IV High-Risk Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Procedure, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 2
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Procedure, Biological, Other
Study Drug: Nivolumab
Study Phase: Phase 3
Phase II Randomized Trial of Avelumab Plus Cetuximab Versus Avelumab Alone in Advanced Cutaneous Squamous Cell Carcinoma of the Skin (cSCC)
Phase II Randomized Trial of Avelumab Plus Cetuximab Versus Avelumab Alone in Advanced Cutaneous Squamous Cell Carcinoma of the Skin (cSCC)
Enrollment Status: Active_not_recruiting
Publish Date: February 18, 2025
Intervention Type: Drug
Study Drugs: Avelumab, Cetuximab
Study Phase: Phase 2
A Phase II Randomized Study of Nivolumab (NSC-748726) With Ipilimumab (NSC-732442) or Ipilimumab Alone in Advanced Melanoma Patients Refractory to an Anti-PD1 or Anti-PD-L1 Agent
A Phase II Randomized Study of Nivolumab (NSC-748726) With Ipilimumab (NSC-732442) or Ipilimumab Alone in Advanced Melanoma Patients Refractory to an Anti-PD1 or Anti-PD-L1 Agent
Enrollment Status: Completed
Publish Date: January 13, 2025
Intervention Type: Biological
Study Drugs: Ipilimumab, Nivolumab
Study Phase: Phase 2
A Prospective, Randomized, Blinded, Placebo-controlled, Phase IIb Trial of an Autologous Tumor Lysate (TL) + Yeast Cell Wall Particles (YCWP) + Dendritic Cells (DC) Vaccine vs Unloaded YCWP + DC and Embedded Phase I/IIa Trial With Tumor Lysate Particle Only (TLPO) Vaccine in Stage III and Stage IV (Resected) Melanoma to Prevent Recurrence.
A Prospective, Randomized, Blinded, Placebo-controlled, Phase IIb Trial of an Autologous Tumor Lysate (TL) + Yeast Cell Wall Particles (YCWP) + Dendritic Cells (DC) Vaccine vs Unloaded YCWP + DC and Embedded Phase I/IIa Trial With Tumor Lysate Particle Only (TLPO) Vaccine in Stage III and Stage IV (Resected) Melanoma to Prevent Recurrence.
Enrollment Status: Completed
Publish Date: November 29, 2024
Intervention Type: Drug
Study Drug: Tumor Lysate, Particle-Loaded, Dendritic Cell Vaccine
Study Phase: Phase 2
A Phase 1, Open-label, Dose-escalation Study of SEA-CD40 in Adult Patients With Advanced Malignancies
A Phase 1, Open-label, Dose-escalation Study of SEA-CD40 in Adult Patients With Advanced Malignancies
Enrollment Status: Terminated
Publish Date: May 01, 2023
Intervention Type: Drug
Study Drugs: SEA-CD40, Pembrolizumab, Gemcitabine, Nab-Paclitaxel
Study Phase: Phase 1
A Phase I and Expansion Cohort Study of Adjuvant Cisplatin, Intensity-Modulated Radiotherapy, and MK-3475 (Pembrolizumab) in High-Risk Head and Neck Squamous Cell Carcinoma (HNSCC)
A Phase I and Expansion Cohort Study of Adjuvant Cisplatin, Intensity-Modulated Radiotherapy, and MK-3475 (Pembrolizumab) in High-Risk Head and Neck Squamous Cell Carcinoma (HNSCC)
Enrollment Status: Completed
Publish Date: June 10, 2022
Intervention Type: Drug, Other, Radiation, Biological
Study Drugs: Cisplatin, Pembrolizumab
Study Phase: Phase 1
A Phase 1b Study of LY2835219 in Combination With Multiple Single Agent Options for Patients With Stage IV NSCLC
A Phase 1b Study of LY2835219 in Combination With Multiple Single Agent Options for Patients With Stage IV NSCLC
Enrollment Status: Completed
Publish Date: September 11, 2020
Intervention Type: Drug
Study Phase: Phase 1
View 8 Less Clinical Trials

29 Total Publications

Reply to: Enfortumab Vedotin: A Promising Therapy for Head and Neck Cancer With Potential Links to Human Papillomavirus.
Reply to: Enfortumab Vedotin: A Promising Therapy for Head and Neck Cancer With Potential Links to Human Papillomavirus.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: February 19, 2025
Similar Doctors
Distinguished in Angiosarcoma of the Scalp
Dr. Shlomo Koyfman
Otolaryngology
Distinguished in Angiosarcoma of the Scalp
Dr. Shlomo Koyfman
Otolaryngology

Cleveland Clinic Main Campus

10201 Carnegie Avenue, 
Cleveland, OH 
 (0.3 miles away)
866-223-8100
Experience:
23+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Shlomo Koyfman is an Otolaryngologist in Cleveland, Ohio. Dr. Koyfman has been practicing medicine for over 23 years and is rated as an Elite provider by MediFind in the treatment of Angiosarcoma of the Scalp. His top areas of expertise are Laryngeal Cancer, Throat Cancer, Head and Neck Squamous Cell Carcinoma (HNSCC), Laryngectomy, and Thyroidectomy.

Advanced in Angiosarcoma of the Scalp
Dr. Brandon Prendes
Otolaryngology
Advanced in Angiosarcoma of the Scalp
Dr. Brandon Prendes
Otolaryngology

Cleveland Clinic Main Campus

2049 East 100th Street, 
Cleveland, OH 
 (0.2 miles away)
216-444-2200
Experience:
21+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Brandon Prendes is an Otolaryngologist in Cleveland, Ohio. Dr. Prendes has been practicing medicine for over 21 years and is rated as a Distinguished provider by MediFind in the treatment of Angiosarcoma of the Scalp. His top areas of expertise are Throat Cancer, Laryngeal Cancer, Salivary Gland Tumors, Laryngectomy, and Thyroidectomy.

Jamie Ku
Advanced in Angiosarcoma of the Scalp
Dr. Jamie Ku
Otolaryngology
Advanced in Angiosarcoma of the Scalp
Dr. Jamie Ku
Otolaryngology

Cleveland Clinic Main Campus

2049 East 100th Street, 
Cleveland, OH 
 (0.2 miles away)
216-444-2200
Languages Spoken:
English, Korean
See accepted insurances

Jamie Ku is an Otolaryngologist in Cleveland, Ohio. Dr. Ku is rated as a Distinguished provider by MediFind in the treatment of Angiosarcoma of the Scalp. Her top areas of expertise are Salivary Gland Tumors, Acinic Cell Carcinoma of Salivary Glands, Mikulicz Disease, Laryngectomy, and Gastrostomy.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Yilmaz's expertise for a condition
ConditionClose
View All 17 Advanced Conditions
View All 12 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile